Orthofix 3Q 2026: Revenue $207.86M, EPS ($0.15) — 10-Q Summary
Orthofix reported 3Q 2026 revenue of $207.86M, up 1.1% YoY, with a net loss of $6.07M, improved from $22.8M last year. Therapeutic Solutions and Global Limb Reconstruction sales grew, while Spinal Implants and other segments declined. Gross margin fell to 70.5% due to product mix changes. SG&A expenses decreased by $22.8M, driven by lower legal costs and commissions.
How this was made
The 30-second read
Why it matters
The earnings release narrows the quarterly loss and improves EPS, offering a modest catalyst for the stock.
Market read
Primary earnings disclosure for a small‑cap medical device firm; modest trading relevance.
What to watch
Potential supply‑chain delays and legal cost reductions may not be sustainable.
Background
Orthofix Medical Inc. filed its Q3 2026 Form 10‑Q, providing detailed financials and segment performance.
Ticker impact
Q3 2026 net sales rose 1.1% YoY to $207.86M and net loss narrowed to $6.07M, improving EPS to -$0.15.
modest upside as the market prices in the narrowed loss and improved EPS
First‑report earnings release with better‑than‑expected loss; revenue growth is modest, margin decline tempers enthusiasm.
Market effects
Slightly positive for the medical device sector as loss narrowing may signal improving demand.
Limited to US‑listed medical‑device stocks.
Low; impact confined to niche investors.
Counterpoint
Margin compression and weak spine implant sales could outweigh loss narrowing, leading to downside.
Key entities
- companyOrthofix Medical Inc.
US‑listed medical‑device manufacturer.
